A useful side effect of Neupogen
The first medicine for victims of nuclear explosions approved in the United States
The drug, which has been used for a long time to relieve the side effects of chemotherapy, was allowed to be used in the United States to eliminate the consequences of radiation exposure during nuclear disasters. This is reported by the publication Gizmag (with reference to a more detailed source, the press release "University of Maryland School of Medicine Research Leads To FDA Approval of First Drug To Treat Radiation Sickness" - VM).
Neupogen (filgrastim trademark) is a synthetic protein that stimulates the growth of white blood cells (an important tool of the immune system responsible for resisting infections). When the production of leukocytes decreases during chemo and radiotherapy, neupogen accelerates the growth, maturation and release of white blood cells from the bone marrow.
As such, this medication was approved back in 1991, but only now the US Food and Drug Administration has approved the outcome of many years of research at the University of Maryland (FDA Approves Radiation Medical Countermeasures). Neupogen became the first officially recognized drug for the treatment of hematopoietic (hematopoiesis-related) aspects of acute radiation sickness (H-ARS).
American doctors conducted clinical trials on animals, since there are currently practically no people affected by powerful nuclear explosions. The Department found the tests adequate enough to recommend neupogen. This drug reduces the severity of the lesion and accelerates the recovery of bone marrow that has received large doses of radioactive radiation.
Neupogen reserves have already been included in the US Strategic National Reserve – a repository of antibiotics, vaccines, antidotes and other means created for prompt distribution to the population in the event of a chemical, biological or radiation disaster.
Portal "Eternal youth" http://vechnayamolodost.ru28.05.2015